ELL2 and inflammatory bowel disease: We utilized microarray technology to conduct a Pan-therapy Analysis and identify two key gene signatures (DAPP1 and ELL2) as biomarkers of unresponsiveness to multiple therapies and inflammatory progression in IBD.